Research programme: chimeric antigen receptor T cell therapeutics - Noile-Immune Biotech/Takeda Oncology

Drug Profile

Research programme: chimeric antigen receptor T cell therapeutics - Noile-Immune Biotech/Takeda Oncology

Latest Information Update: 08 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Yamaguchi University
  • Developer Noile-Immune Biotech; Takeda Oncology
  • Class Antineoplastics; CAR-T cell therapies; Immunotherapies
  • Mechanism of Action Cell replacements; Cytotoxic T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 04 Sep 2017 Noile-Immune Biotech and Takeda agree to research and develop CAR-T cells for Solid tumours
  • 04 Sep 2017 Preclinical trials in Solid tumours in Japan (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top